Drug Profile
Seletalisib - UCB
Alternative Names: UCB-5857Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator UCB
- Class Amines; Anti-inflammatories; Antipsoriatics; Chlorobenzenes; Fluorinated hydrocarbons; Pyridines; Pyridones; Pyrimidines; Quinolines; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunodeficiency disorders; Plaque psoriasis; Sjogren's syndrome
Most Recent Events
- 12 Jun 2019 Efficacy and adverse events data from a phase II trial in Sjogren's syndrome presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Immunodeficiency-disorders(In adolescents, In adults) in France (PO, Capsule)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Immunodeficiency-disorders(In adolescents, In adults) in Germany (PO, Capsule)